Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Azzak34on Apr 11, 2024 12:28pm
89 Views
Post# 35983561

RE:RE:RE:RE:Type C Meeting Timings

RE:RE:RE:RE:Type C Meeting Timings
RE:RE:RE:Type C Meeting Timings
Having to hold a Type C meeting means there are questions ONCY has that they wish addressing...

great insight, thathat's the whole point of the meeting stupid.  

Yes, it probably is related to potential biomarkers, and whether or not FDA will accept ONCY's suggested biomarker... the text of the new release still states potential, and not CONFIRMED...

Probably? That's exaclty what it's for! That's great news for us. 

So, this Type C meeting isn't exactly the one we want to be in...as it would be quicker simply to get on with the Phase III trial design, as per their SPA issued by FDA 6 years ago...

noteable already embarrassed you on this one. Didnt you already day we had abandoned Breast though and it was left behind due to a lack of positive results?? 

AFTER the FDA has fed back its responses either verbally or electronically (a Type C meeting does not have to face to face), only then can they write their trial protocol, and send that for assessment.

the trial will be be based on the purpose of the meeting! You think they'll not be submitting that or at least started it at the same time dummy? 

SO, motormouth... Feedback will be due Jun 24th, and thereafter ONCY will submit its phase III trial protocol... so NO Phase III before Q4 2024.

it could happen next week, you have no idea when the meeting will happen. Latest is 24th June. Bracelet data is due in the next month or so. You worried? 


Jeez... and I see the market has reacted accordingly to this fabulous news... down already...LOL

Hahahahah last 30 days Crispr down 20% BYON down 20%!!!! You have no idea what you're doing!!!! 
<< Previous
Bullboard Posts
Next >>